Structure Therapeutics reported a net loss of $106.2 million for the second quarter 2026, driven by a substantial increase in research and development spending. The company remains well-capitalized with $1.3 billion in liquidity, which management expects to provide a cash runway through the end of 2028.
Key Highlights
- Dosed first patients in the Phase 3 ACCOMPLISH program evaluating aleniglipron, an oral GLP-1 receptor agonist, for chronic weight management.
- R&D expenses increased 83% year-over-year to $100.1 million, primarily due to the initiation of late-stage clinical trials and headcount expansion.
- Clinical momentum continues with initial Phase 1 data for amylin agonist ACCG-2671 on track for Q3 2026 and a combination trial initiation expected in Q4 2026.